For some patients with solid cancers, epigenetic changes in RASSF1A can be detected in leukocytes [4], urine [5], nipple aspirates [6] and saliva [7] to support the identification of circulating tumor cells and to highlight non-invasive methods to detect hypermethylation of RASSF1A. Recently, RASSF1A hypermethylation was detected in leukocytes in workers exposed to radiation during the Chernobyl Nuclear Power Plant disaster in Russia in 1986 [8] to suggest a high susceptibility of the RASSF1A promoter to epigenetic modifications. Here, RASSF1 is linked to neoplasm.